CTOs on the Move

Defense Health Agency

www.health.mildha

 
The DHA is a joint, integrated Combat Support Agency that enables the Army, Navy, and Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime. The DHA supports the delivery of integrated, affordable, and high quality health services to 9.5 million Military Health System beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS. The DHA oversees the delivery of health care services like the TRICARE Health Plan, pharmacy, public health, and health information technology. DHA carries out these operations using a ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.health.mildha
  • 7700 Arlington Boulevard Suite 5101
    Falls Church, VA USA 22042
  • Phone: 888.647.6676

Executives

Name Title Contact Details
Lisa Belter
Chief Technology Officer Profile

Similar Companies

Innovative Therapies

Innovative Therapies is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Peace River Community Services

Peace River Community Services is a Grande Prairie, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ScribeAmerica

ScribeAmerica is a Lancaster, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triangle Aids Network

Triangle Aids Network is a Beaumont, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.